For Free Headlines Submit Your Email
Thursday, April 27, 2017
Minister of Public Health Dr Hanan Mohammed Al Kuwari inaugurated expansion works and new production lines of Qatar Pharma company on Wednesday. The expansion adds eight new production lines, bringing the total number of production lines to 14. Dr Hanan Mohammed Al Kuwari stressed the keenness of the Ministry of Public Health to support pharmaceutical industries in the State of Qatar and its high quality in accordance with the best international standards. In a press statement, she highlighted the modernity of the pharmaceutical industries in the country, stressing the efforts aimed at strengthening this strategic industry through constructive cooperation with the private sector, and thus contribute to meet an important aspect of the local market's needs in this area. During her visit to the factory, Dr. Al Kuwari was briefed on the new production lines, stages of production and pharmaceutical industries. Qatar Pharma started its production operations in 2009 and is currently producing dialysis solutions, intravenous solutions, dehydration solutions, ointments, eye drops, and medical supplies that complement the production process. For his part, Dr Ahmed Mohammad Al Sulaiti, Chairman of Qatar Pharma, said the company has exported nearly 90% of its production to all GCC markets and some Arab countries such as Jordan, Iraq, Yemen, Sudan and Libya after covering all the needs of the local market. He pointed out that Qatar Pharma is currently exporting to Europe after obtaining the European certificate of conformity which qualifies it for export to European countries, adding that Qatar Pharma is one of the largest exporting companies in Qatar and has managed to increase its sales since the start of the production process. The plant started with two stages of production and witnessed and expansion, which reached currently 14 lines, he said, noting that the Board of Directors which took place in the first week of April has taken a decision to become a public shareholding company in order to enhance financial, human and technical capabilities, increase market shares, move to global competition with international companies and revitalize the stock market. The total assets exceeded QR320 million (~US$88 million), he went on saying. Dr Al Sulaiti said that the new expansions in the plant's work and its production lines are in line with Qatar National Vision (QNV) 2030 and in response to the quest of many investors to participate in this pharmaceutical facility and opening new markets.
© 2017 BEDigest. All Rights Reserved.